Area under the curve (AUC) findings, across different BC subtypes (Figure 1, Supplementary Figure S2), indicates that NEDD9 is a strong prognostic biomarker of anti-HER2 and FEC therapy response in HER2+ BC patients. Here, ERBB2 is linked to breast cancer.